

---



1

1.1

1

2022

2019 9

2019 12 2022

20

2020 1

2020 4

2022

8



2

2022



3

ED

50mg

-

5mg

-

100mg



4

(2019 )

2016

2018

2016

ESC/EAS

2022

2021



通诺安®  
利伐沙班片



清诺安®  
匹伐他汀钙片

1.2

1

Tab in tab

A2 TXA2

ADP

ADP

GP b/

ADP

Sanofi Clir SNC

2021 9

2021 /

/

2023 2

2

UDCA

UDCA

UDCA

UDCA

FDA

2021

20

16%

74.61%

20.58%

2022 10

3

5-

18-64

(PE)

2023 2 20

MAH

2023 3 30

MAH

CDE

4

sofosbuvir

1

2017 9

2018

34494

36170

2019 8

CDE

2

2015 IPO

GST-

HG171 II/III

GST-HG141 II

**1** **GST-HG171**

GST-HG171 3CL 3C-like protease 3CLpro  
3CL

I IIT Paxlovid Paxlovid

GST-HG171

GST-HG171 150mg Paxlovid 300mg

RAY1216 400mg

SIM0417 750mg

GST-HG171 II/III

**2** **c-Met** **GST-HG161**

c-Met GST-HG161 c-Met

c-Met

c-Met GST-HG161 I

Ib

3

CSCO

CSCO

GST-HG161 II PI GST-HG161

WHO INN

GST-HG161 PCT 20

6

**3** **GST-HG151**

GST-HG151

GST-HG151 NASH

GST-HG151 2019 4

2022 3 11

I

GST-HG151 PCT 16

4

**4** **GST-HG121/131/141**

2015 GST-HG131/GST-HG121 GST-HG141

2017 AASLD

EASL

**GST-HG141** HBVcccDNA First in class MOA II

GST-HG141 2019 11 I GST-HG141





---





---

2023 3

2023 3 3